| |
| |
|
| Insider
Information: |
Kauffman Michael |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
800,347 |
|
|
Indirect Shares
|
898,131 |
|
|
| Direct
Value |
$881,257 |
|
|
|
Indirect Value
|
$916,094 |
|
|
| Total
Shares |
1,698,478 |
|
|
| Total
Value |
$1,797,350 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
12
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
12
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-12.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -553.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
Chief Medical Officer |
2010-02-09 |
9,000 |
2009-11-16 |
0 |
Premium* |
|
|
Karyopharm Therapeutics Inc. |
KPTI |
Director |
2022-02-28 |
713,757 |
2022-02-28 |
898,131 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
Director |
2018-09-28 |
8,000 |
2014-09-17 |
0 |
Premium* |
|
|
Kezar Life Sciences, Inc. |
KZR |
Director |
2022-01-03 |
63,690 |
2018-06-25 |
0 |
Premium* |
|
|
Adicet Bio, Inc |
ACET |
Director |
2023-06-01 |
5,900 |
2023-06-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
156 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KPTI |
Karyopharm Therapeutics I... |
President, C.E.O., C.M.O.Offic |
• • – |
2013-11-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
620,771 |
|
- |
|
| KPTI |
Karyopharm Therapeutics I... |
President, C.E.O., C.M.O.Offic |
• • – |
2013-11-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,001,713 |
|
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2009-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chief Medical Officer |
• – – |
2010-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,000 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
President, CEO & CMO |
• • – |
2013-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
132,575 |
753,346 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2013-12-20 |
5 |
GD |
$0.00 |
$0 |
D/D |
55,750 |
697,596 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2013-12-20 |
5 |
GD |
$0.00 |
$0 |
I/I |
82,750 |
918,963 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2014-12-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
20,000 |
788,963 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2015-12-30 |
5 |
GD |
$0.00 |
$0 |
I/I |
3,144 |
760,819 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2015-12-30 |
5 |
GD |
$0.00 |
$0 |
D/D |
3,144 |
559,452 |
0 |
- |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,516 |
63,690 |
0 |
- |
|
| VSTM |
Verastem, Inc. |
Director |
– • – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
8,000 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2019-12-19 |
4 |
GD |
$0.00 |
$0 |
I/I |
34,626 |
0 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,800 |
563,939 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2020-02-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
21,800 |
765,306 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,300 |
569,422 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
14,300 |
770,789 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,800 |
584,621 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-15 |
4 |
OE |
$0.00 |
$0 |
I/I |
21,800 |
785,947 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
57,200 |
718,826 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
I/I |
57,200 |
920,152 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Director |
– • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
719,983 |
0 |
- |
|
| ACET |
Adicet Bio, Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
5,900 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-06-07 |
4 |
OE |
$0.03 |
$2,570 |
I/I |
10,000 |
723,510 |
0 |
- |
|
| KPTI |
Karyopharm Therapeutics I... |
Chief Executive Officer |
• • – |
2018-07-09 |
4 |
OE |
$0.03 |
$413 |
I/I |
12,500 |
726,010 |
0 |
- |
|
156 Records found
|
|
Page 1 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
